Diminished insulin action in the vasculature may contribute to the developm
ent of cardiovascular diseases in diabetes. me have studied insulin's effec
ts on the phosphatidylinositol (PI) 3-kinase pathway in arterial smooth mus
cle cells (SMCs) and its inhibition by endothelin (ET)-1, a potent vasoacti
ve hormone reported to be elevated in insulin resistance and other vascular
diseases. ET-1 increased the level of serine phosphorylation of insulin re
ceptor beta subunit but increased both tyrosine and serine phosphorylation
of insulin receptor substrate (IRS)-2. Pretreatment of cells with ET-1 (10
nmol/l) inhibited insulin-stimulated PI 3-kinase activity associated with I
RS-2 by 50-60% and inhibited the association of p85 subunit of PI 3-kinase
to IRS-2. The inhibition of insulin-stimulated PI 3-kinase activity by ET-1
was prevented by BQ-123, a selective ET, receptor antagonist, but was not
affected by pertussis toxin. Treatment of cells with phorbol 12-myristate 1
3-acetate, an activator of protein kinase C (PKC), reduced both insulin-sti
mulated PI 3-kinase activity by 57% and the association of IRS-2 to the p85
subunit of PI 3-kinase by 40%, whereas GF109203X, a specific inhibitor of
PKC, partially prevented the inhibitory effect of ET-1 on insulin-induced P
I 3-kinase activity. These results suggested that ET-1 could interfere with
insulin signaling in SMCs by both PKC-dependent and -independent pathways.